A phase I, double-blind, randomized, placebo-controlled study of the safety and reactogenicity of a single oral dose of the SmithKline Beecham Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy adults aged 18 to 45 years, Trial ID 444563%2F001

A phase I, double-blind, randomized, placebo-controlled study of the safety and reactogenicity of a single oral dose of the SmithKline Beecham Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy adults aged 18 to 45 years, Trial ID 444563%2F001 | GSK